MEDPACE HOLDINGS, INC. (NASDAQ:MEDP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 15, 2017, Alexander F.S. Leslie, a member of the Board of Directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) and a member of the Compensation Committee thereof, notified the Board of his resignation, effective as of June 15, 2017. On June 14, 2017, Matthew R. Norton, a member of the Board of the Company, notified the Board of his resignation, effective as of June 15, 2017. Mr. Leslie and Mr. Norton’s resignations did not result from any disagreement with the Company on any matter relating to its operations, policies or practices.
Cinven nominated and the Board elected John R. Richardson and Anastasya Molodykh as Class II Directors, to fill, respectively, the vacancies on the Board created by Mr. Leslie and Mr. Norton’s resignations. The Board also appointed Mr. Richardson to serve as a member of the Compensation Committee. The elections of Mr. Richardson and Ms. Molodykh were effective immediately following the effectiveness of Mr. Leslie and Mr. Norton’s resignations. Mr. Richardson and Ms. Molodykh shall each hold office until the Company’s 2018 Annual Meeting of Stockholders and until his/her respective successor shall be elected and qualified.
Mr. Richardson joined Cinven in 2017, has been a senior principal since May 2017 and is a member of Cinven’s Healthcare sector team, and the Americas regional team. Prior to joining Cinven, he worked at Metalmark Capital where he co-led the Healthcare sector team. Before joining Metalmark, he worked at Citadel, Cressey & Company and Merrill Lynch. Mr. Richardson has extensive experience serving as a director for a diverse group of U.S. private companies. Mr. Richardson has an MBA from Harvard Business School and a BE in Biomedical Engineering from Vanderbilt University.
Ms. Molodykh joined Cinven in 2015 and is a member of Cinven’s Healthcare sector team and the UK & Ireland’s regional team. Prior to joining Cinven, she worked in the Investment Banking Division of Deutsche Bank in London from 2010 to 2015 advising on M&A and carve-out deals across a range of sectors. At Cinven, Ms. Molodykh has been involved in a number of investments including Synlab.
Mr. Richardson and Ms. Molodykh will each participate in the Company’s standard compensation program for non-employee directors who are affiliates of Cinven Capital Management (V) General Partner Limited, which shall consist of an annual cash retainer of $40,000. An additional annual retainer of $7,500 will be paid for Mr. Richardson’s service on the Compensation Committee. The annual cash retainer fees earned by Mr. Richardson and Ms. Molodykh will be paid directly to Cinven and not to Mr. Richardson and Ms. Molodykh individually. The Company expects to enter into the Company’s standard indemnification agreement for directors and officers with Mr. Richardson and Ms. Molodykh.
Cinven and the Company are parties to an Advisory Services Agreement, Voting Agreement and Registration Rights Agreement which are described in the Company’s proxy materials filed on Schedule 14A with the Securities and Exchange Commission on April 5, 2017. The description of these agreements in the proxy materials under the section captioned “Certain Relationships” is incorporated herein by reference.
About MEDPACE HOLDINGS, INC. (NASDAQ:MEDP)
Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.